| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from out-licensing | 300 | - |
| Net cash used in investing activities | -20 | -320 |
| Proceeds from exercise of warrants | 487 | 487 |
| Proceeds from issuance of ordinary shares | 0 | 0 |
| Transaction costs on issuance of ordinary shares | 199 | 199 |
| Net cash provided by financing activities | 288 | 288 |
| (decrease)/increase in cash and cash equivalents | -23,021 | -16,012 |
| Cash and cash equivalents at beginning of period | 69,802 | - |
| Effect of exchange rate changes on cash | 1,917 | - |
| Cash and cash equivalents at end of period | 48,698 | - |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)